Glycyrrhizic acid attenuated glycative stress in kidney of diabetic mice through enhancing glyoxalase pathway

Molecular Nutrition and Food Research

Volumn 58, Issue 7, 2014, Pages 1426-1435

  Wang, Zhi hong ^a   Hsieh, Cheng Hong ^b   Liu, Wen hu ^c   Yin, Mei chin ^b,d  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b ASIA UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Diabetic nephropathy; Glycation; Glycyrrhizic acid; Glyoxalase 1; Methylglyoxal

Indexed keywords

ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ALDEHYDE REDUCTASE; CCL2 PROTEIN, MOUSE; FRUCTOSE; GLUTATHIONE; GLYCYRRHIZIC ACID; HYDROXYACYLGLUTATHIONE HYDROLASE; ICAM1 PROTEIN, MOUSE; IDITOL DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; LACTOYLGLUTATHIONE LYASE; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; SORBITOL; THIOL ESTER HYDROLASE;

ANIMAL; BAGG ALBINO MOUSE; DIABETES MELLITUS, EXPERIMENTAL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; KIDNEY; MALE; METABOLISM; MOUSE; OXIDATIVE STRESS; URINE;

ALDEHYDE REDUCTASE; ANIMALS; CHEMOKINE CCL2; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FRUCTOSE; GLUTATHIONE; GLYCYRRHIZIC ACID; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY; L-IDITOL 2-DEHYDROGENASE; LACTOYLGLUTATHIONE LYASE; MALE; MICE; MICE, INBRED BALB C; NF-KAPPA B; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC; SORBITOL; THIOLESTER HYDROLASES;

EID: 84903550187     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300910     Document Type: Article

References (40)

1. Kalousová, M., Zima, T., Tesar, V., Dusilová-Sulková et al., Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat. Res. 2005, 579, 37-46.
2. Chao, P. C., Huang, C. N., Hsu, C. C., Yin, M. C. et al., Association of dietary AGEs with circulating AGEs, glycated LDL, IL-1α and MCP-1 levels in type 2 diabetic patients. Eur. J. Nutr. 2010, 49, 429-434.
3. Dunlop, M., Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int. 2000, 58, 3-12.
4. Rabbani, N., Thornalley, P. J., Glyoxalase in diabetes, obesity and related disorders. Semin. Cell Dev. Biol. 2011, 22, 309-317.
5. Thornalley, P. J., Glyoxalase I-structure, function and a critical role in the enzymatic defence against glycation. Biochem. Soc. Trans. 2003, 31, 1343-1348.
6. Xie, J., Méndez, J. D., Méndez-Valenzuela, V., Aguilar-Hernández, M. M., Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal 2013, 25, 2185-2197.
7. Jensen, L. J., Østergaard, J., Flyvbjerg, A., AGE-RAGE and AGE Cross-link interaction: important players in the pathogenesis of diabetic kidney disease. Horm. Metab. Res. 2005, 37, 26-34.
8. Grossin, N., Wautier, M. P., Meas, T., Guillausseau, P. J. et al., Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab. 2008, 34, 392-395.
9. Ming, L. J., Yin, A. C., Therapeutic effects of glycyrrhizic acid. Nat. Prod. Commun. 2013, 8, 415-418.
10. Wang, C. Y., Kao, T. C., Lo, W. H., Yen, G. C., Glycyrrhizic acid and 18β-glycyrrhetinic acid modulate lipopolysaccharide-induced inflammatory response by suppression of NF-κB through PI3K p110δ and p110γ inhibitions. J. Agric. Food Chem. 2011, 59, 7726-7733.
11. Asl, M. N., Hosseinzadeh, H., Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother. Res. 2008, 22, 709-724.
12. Ko, B. S., Jang, J. S., Hong, S. M., Sung, S. R. et al., Changes in components, glycyrrhizin and glycyrrhetinic acid, in raw Glycyrrhiza uralensis Fisch, modify insulin sensitizing and insulinotropic actions. Biosci. Biotechnol. Biochem. 2007, 71, 1452-1461.
13. Sen, S., Roy, M., Chakraborti, A. S., Ameliorative effects of glycyrrhizin on streptozotocin-induced diabetes in rats. J. Pharm. Pharmacol. 2011, 63, 287-296.
14. Feng, L., Zhu, M. M., Zhang, M. H., Wang, R. S. et al., Protection of glycyrrhizic acid against AGEs-induced endothelial dysfunction through inhibiting RAGE/NF-κB pathway activation in human umbilical vein endothelial cells. J. Ethnopharmacol. 2013, 148, 27-36.
15. Gao, Q. T., Chen, X. H., Bi, K. S., Comparative pharmacokinetic behavior of glycyrrhetic acid after oral administration of glycyrrhizic acid and Gancao-Fuzi-Tang. Biol. Pharm. Bull. 2004, 27, 226-228.
16. Miyata, T., Taneda, S., Kawai, R., Ueda, Y. et al., Identification of pentosidine as a native structure for advanced glycation end products in β2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 2353-2358.
17. Nishinaka, T., Yabe-Nishimura, C., EGF receptor-ERK pathway is the major signaling pathway that mediates upregulation of aldose reductase expression under oxidative stress. Free Radic. Biol. Med. 2001, 31, 205-216.
18. Ulrich, H. B. in: Bergmeyer, H. U., (Ed.), Methods of Enzyme Analysis, vol. 2, Academic press, New York 1974, pp. 567-573.
19. Masterjohn, C., Mah, E., Park, Y., Pei, R. et al., Acute glutathione depletion induces hepatic methylglyoxal accumulation by impairing its detoxification to D-lactate. Exp. Biol. Med. 2013, 238, 360-369.
20. Guerrant, G., Moss, C. W., Determination of monosaccharides as aldononitrile, O-methyoxime, alditol, and cyclitol acetate derivatives by gas chromatography. Anal. Chem. 1984, 56, 633-638.
21. Chaplen, F. W., Fahl, W. E., Cameron, D. C., Method of determination of free intracellular and extracellular methylglyoxal in animal cells grown in culture. Anal. Biochem. 1996, 238, 171-178.
22. Koya, D., Hayashi, K., Kitada, M., Kashiwagi, A. et al., Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J. Am. Soc. Nephrol. 2003, 14, S250-253.
23. Gugliucci, A., Bendayan, M., Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1997, 39, 149-160.
24. Schleicher, E. D., Wagner, E., Nerlich, A. G., Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 1997, 99, 457-468.
25. Maekawa, K., Tanimoto, T., Okada, S., Suzuki, T. et al., Expression of aldose reductase and sorbitol dehydrogenase genes in Schwann cells isolated from rat: effects of high glucose and osmotic stress. Brain Res. Mol. Brain Res. 2001, 87, 251-256.
26. Takeuchi, M., Yamagishi, S., Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo. Med. Hypotheses 2004, 63, 453-455.
27. Vander Jagt, D. L., Mthyylglyoxal, diabetes mellitus and diabetic complications. Drug Metabol. Drug Interact. 2008, 23, 93-124.
28. Jack, M. M., Ryals, J. M., Wright, D. E., Protection from diabetes-induced peripheral sensory neuropathy:a role for elevated glyoxalase I? Exp. Neurol. 2012, 234, 62-69.
29. Beisswenger, P. J., Howell, S. K., Russell, G. B., Miller, M. E. et al., Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products. Diabetes Care 2013, 36, 3234-3239.
30. Schmidt, A. M., Stern, D. M., RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrin. Met. 2000, 13, 368-375.
31. Maeda, S., Matsui, T., Takeuchi, M., Yoshida, Y. et al., Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacol. Res. 2011, 63, 241-248.
32. Santilli, F., Vazzana, N., Bucciarelli, L. G., Davi, G., Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr. Med. Chem. 2009, 16, 940-952.
33. Antognelli, C., Gambelunghe, A., Talesa, V. N., Muzi, G., Reactive oxygen species induce apoptosis in bronchial epithelial BEAS-2B cells by inhibiting the antiglycation glyoxalase I defence: involvement of superoxide anion, hydrogen peroxide and NF-κB. Apoptosis 2014, 19, 102-116.
34. Motawi, T. M., Abou-Seif, M. A., Bader, A. M., Mahmoud, M. O., Effect of glycemic control on soluble RAGE and oxidative stress in type 2 diabetic patients. BMC Endocr. Disord. 2013, 13, 32.
35. Sato, H., Takahashi, T., Ide, H., Fukushima, T. et al., Antioxidant activity of synovial fluid, hyaluronic acid, and two subcomponents of hyaluronic acid. Synovial fluid scavenging effect is enhanced in rheumatoid arthritis patients. Arthritis Rheum. 1988, 31, 63-71.
36. Stickel, F., Schuppan, D., Herbal medicine in the treatment of liver diseases. Dig. Liver Dis. 2007, 39, 293-304.
37. Houssen, M. E., Ragab, A., Mesbah, A., El-Samanoudy, A. Z. et al., Natural anti-inflammatory products and leukotriene inhibitors as complementary therapy for bronchial asthma. Clin. Biochem. 2010, 43, 887-890.
38. Ikeda, K., Arase, Y., Kobayashi, M., Saitoh, S. et al., A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig. Dis. Sci. 2006, 51, 603-609.
39. Mumoli, N., Cei, M., Licorice-induced hypokalemia. Int. J. Cardiol. 2008, 124, 42-44.
40. Celik, M. M., Karakus, A., Zeren, C., Demir, M. et al., Licorice induced hypokalemia, edema, and thrombocytopenia. Hum. Exp. Toxicol. 2012, 31, 1295-1298.